Subject(s)
Antibodies, Monoclonal/adverse effects , Carcinoma, Merkel Cell/drug therapy , Carcinoma, Merkel Cell/secondary , Thrombocytopenia/chemically induced , Aged , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Carcinoma, Merkel Cell/pathology , Fatal Outcome , Humans , Male , Purpura, Thrombocytopenic, Idiopathic/chemically inducedSubject(s)
Leukemia, Myeloid, Acute/pathology , Aged , Female , Humans , Leukemia, Myeloid, Acute/therapySubject(s)
Carcinoma, Squamous Cell/chemically induced , Indoles/administration & dosage , Melanoma/drug therapy , Peripheral Nervous System Neoplasms/chemically induced , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Skin Neoplasms/drug therapy , Sulfonamides/administration & dosage , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Carcinoma, Squamous Cell/pathology , Diagnosis, Differential , Female , Humans , Indoles/adverse effects , Keratoacanthoma/chemically induced , Keratoacanthoma/pathology , Melanoma/pathology , Neoplasm Invasiveness , Peripheral Nervous System Neoplasms/pathology , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/adverse effects , Skin Neoplasms/complications , Sulfonamides/adverse effects , Treatment Outcome , VemurafenibSubject(s)
Carcinoma, Verrucous/chemically induced , Indoles/adverse effects , Melanoma/secondary , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Sarcoma/chemically induced , Skin Neoplasms/chemically induced , Sulfonamides/adverse effects , Aged, 80 and over , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Carcinoma, Verrucous/pathology , Diagnosis, Differential , Female , Humans , Indoles/therapeutic use , Melanoma/drug therapy , Sarcoma/pathology , Skin Neoplasms/drug therapy , Sulfonamides/therapeutic use , Treatment Outcome , VemurafenibABSTRACT
Multiple cutaneous and subcutaneous melanoma metastases represent a therapeutic challenge. A 63-year-old man presented with multiple cutaneous and subcutaneous melanoma metastases on his right parieto-occipital region that appeared ten weeks after surgical excision of the primary tumor. Staging showed no further metastases. Because of the large area of cutaneous metastatic spread, the location and the limited possibility of a complete excision, we decided to begin immunomodulatory therapy with imiquimod applied for eight hours daily five days a week. After six weeks of imiquimod monotherapy, a partial remission of the cutaneous metastases had occurred. After 17 months, the remission of these metastases was complete. Four months later the patient is still free of cutaneous, visceral, cerebral and lymph node metastases.
